Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Collegium Pharmaceutical (COLL) Research & Development (2016 - 2022)

Collegium Pharmaceutical has reported Research & Development over the past 7 years, most recently at $4.0 million for Q1 2022.

  • For Q1 2022, Research & Development rose 35.94% year-over-year to $4.0 million; the TTM value through Dec 2022 reached $4.0 million, down 57.86%, while the annual FY2022 figure was $4.0 million, 57.86% down from the prior year.
  • Research & Development for Q1 2022 was $4.0 million at Collegium Pharmaceutical, up from $1.6 million in the prior quarter.
  • Over five years, Research & Development peaked at $4.0 million in Q1 2022 and troughed at $1.4 million in Q3 2021.
  • A 5-year average of $2.5 million and a median of $2.5 million in 2019 define the central range for Research & Development.
  • On a YoY basis, Research & Development climbed as much as 38.87% in 2021 and fell as far as 34.91% in 2021.
  • Year by year, Research & Development stood at $2.2 million in 2018, then rose by 6.63% to $2.4 million in 2019, then increased by 3.09% to $2.5 million in 2020, then tumbled by 34.91% to $1.6 million in 2021, then soared by 147.55% to $4.0 million in 2022.
  • Business Quant data shows Research & Development for COLL at $4.0 million in Q1 2022, $1.6 million in Q4 2021, and $1.4 million in Q3 2021.